

**Feasibility of fast turnaround genetic screening for type 1 diabetes risk in newborns –
Recruiting infants for the GPPAD primary prevention study SINT1A**

Annika Fehn (MSc)¹, Ezio Bonifacio (PhD)^{2,3,4}, Elisa Bonnin (PhD)¹, Kristina Casteels (MD)^{5,6}, Melanie Gündert (PhD)¹, Martin Heigermoser¹, Ida Jönsson (MSc)⁷, Olga Kordonouri (MD)⁸, Anja Loff (PhD)², Markus Lundgren (MD)^{7,9}, Mariusz Oltarzewski (PhD)¹⁰, Catherine Owen (PhD)¹¹, Steve Robson (MD)¹¹, Anne Rochtus^{5,6}, Frank Roloff (PhD)⁸, Agnieszka Szypowska (MD)^{12,13}, Andreas Weiß (MSc)¹, Christiane Winkler (PhD)^{1,14}, Anette-Gabriele Ziegler (MD)^{1,14}, Florian Haupt (PhD)^{1,14}

Affiliations

1 Institute of Diabetes Research, Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany

2 Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany

3 Paul Langerhans Institute Dresden of Helmholtz Munich at University Hospital Carl Gustav Carus, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany

4 Institute of Diabetes and Obesity (IDO), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany

5 Department of Pediatrics, University Hospital Gasthuisberg, Leuven, Belgium

6 Department of Development and Regeneration, KU Leuven, Leuven, Belgium

7 Unit for Pediatric Endocrinology, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden

8 Kinder- und Jugendkrankenhaus AUF DER BULT, Hanover, Germany

9 Department of Paediatrics, Skåne University Hospital, Kristianstad, Sweden

10 Department of Screening and Metabolic Diagnostics, Institute of Mother and Child, Warsaw, Poland

11 General Paediatrics, The Great North Children's Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, UK

12 Department of Paediatric Diabetology and Paediatrics, The Children's Clinical Hospital Józef Polikarp Brudziński, University Clinical Centre of the Medical University of Warsaw, Warsaw, Poland

13 Department of Paediatric Diabetology and Paediatrics, Medical University of Warsaw, Warsaw, Poland

14 Technical University of Munich, School of Medicine and Health, Forschergruppe Diabetes, TUM University Hospital, Munich, Germany

Corresponding Author: Dr. Florian Haupt, Institute of Diabetes Research, Helmholtz Munich, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany (florian.haupt@helmholtz-munich.de)




Figure 1S. Median ages at each step in the SINT1A (Supplementation with *B. infan is* (EVC001) for Mitigation of Type 1 Diabetes Autoimmunity) screening process, shown per site. The x-axis represents a newborn's age in days. Sites are plotted in the following order, from left to right: Newcastle (UK), Warsaw (Poland), Dresden (Germany), Hanover (Germany), Leuven (Belgium), Malmö (Sweden), and Munich (Germany). Note that no data is available for the sample collection date for Dresden.




Figure 2S. Median ages at each step in the SINT1A (Supplementation with *B. infan is* (EVC001) for Mitigation of Type 1 Diabetes Autoimmunity) screening process, shown according to screening type. The x-axis represents a newborn’s age in days. Screening types are plotted in the following order, from left to right: Combined with national newborn screening (Newcastle, Warsaw), attached to national newborn screening (Dresden, Hanover, Leuven), and independent from national newborn screening (Malmö, Munich). Note that no data is available in the “Sample taken” column for Dresden. Dresden is thus excluded from the analysis in this column but is included in the remainder of the plot.